Neurocrine Biosciences (NBIX) Projected to Post Earnings on Monday

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect Neurocrine Biosciences to post earnings of $0.70 per share and revenue of $587.06 million for the quarter.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Price Performance

NBIX stock traded up $3.09 on Friday, reaching $109.68. The company's stock had a trading volume of 1,700,281 shares, compared to its average volume of 1,071,166. The firm has a fifty day moving average of $106.19 and a two-hundred day moving average of $121.84. The company has a market capitalization of $10.85 billion, a P/E ratio of 33.34, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a 52 week low of $84.23 and a 52 week high of $157.98.

Neurocrine Biosciences declared that its board has initiated a stock buyback program on Friday, February 21st that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 623 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $149.29, for a total transaction of $93,007.67. Following the completion of the sale, the insider now directly owns 3,442 shares in the company, valued at approximately $513,856.18. This trade represents a 15.33 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Julie Cooke sold 700 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $118.28, for a total value of $82,796.00. Following the completion of the transaction, the insider now owns 18,831 shares in the company, valued at $2,227,330.68. This represents a 3.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,530 shares of company stock valued at $1,722,989 over the last quarter. Company insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on NBIX shares. Royal Bank of Canada raised shares of Neurocrine Biosciences from a "sector perform" rating to an "outperform" rating and reduced their price objective for the stock from $138.00 to $137.00 in a report on Monday, April 14th. StockNews.com cut shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Wedbush dropped their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Bank of America decreased their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, William Blair reissued an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Three analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $160.90.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.